TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors. TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. For investors, this announcement matters because it signals continued progress in TransCode's clinical program and provides an opportunity for the company to share data with the global oncology community at a major medical meeting.
The ESMO Congress is one of the most influential gatherings for oncology professionals, and presenting updated Phase 1a data there could raise the profile of TTX-MC138 among researchers, clinicians, and potential partners. The Phase 1a trial is assessing the safety, tolerability, and preliminary activity of TTX-MC138 in patients with advanced solid tumors, a population with significant unmet need. According to the company, TTX-MC138 targets microRNA-10b, a well-documented biomarker of metastasis. By focusing on this mechanism, TransCode aims to address a fundamental driver of cancer spread, which could have broad implications for treating metastatic disease if the approach proves successful.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. In addition to TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The upcoming presentation at ESMO 2026 will be closely watched by investors seeking validation of the company's platform and by clinicians interested in novel therapies for advanced cancers. More details are available in the full press release at https://nnw.fm/sGqsS, and the latest news and updates relating to RNAZ can be found in the company's newsroom at https://nnw.fm/RNAZ.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. IBN also offers editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution to millions of followers. For TransCode, the ESMO presentation represents a key milestone in its efforts to advance TTX-MC138 and could serve as a catalyst for further clinical development and potential partnership discussions.
As the company prepares to share updated Phase 1a data, stakeholders will be looking for signs of clinical benefit and confirmation that the miR-10b targeting approach is safe and tolerable. The results could inform the design of later-stage trials and help determine the future direction of the program. With the ESMO Congress 2026 set for October, the coming months will be a period of anticipation for TransCode and its investors. For more information about NetworkNewsWire and its corporate communications solutions, visit the platform's website. Full terms of use and disclaimers applicable to all content provided by NetworkNewsWire are available at https://www.NetworkNewsWire.com/Disclaimer.
